New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
16:24 EDTLPCNLipocine announces first patient dosed in Phase 2a study of LPCN 1111
Lipocine announced that the first patient has been dosed in a Phase 2a clinical study of LPCN 1111, a novel ester prodrug of testosterone, in hypogonadal males. The primary objectives of the study will be to determine safety, tolerability, single and steady state pharmacokinetics of testosterone following oral administration of LPCN 1111.
News For LPCN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 17, 2014
08:04 EDTLPCNLipocine reports departure of CTO, Chief Business Development Officer
Lipocine announced changes to its executive management team. Changes include the departures of Dr. Srinivasan Venkateshwaran, Chief Technology Officer and vice president Research & Development, effective November 14, and Gerald Simmons, Chief Business Development Officer, effective November 28, 2014. The company has an ongoing search for a Chief Medical Officer and a vice president of Business Development and Commercial.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use